Back to search
FDAFDA · Food and drugs·Recall number D-0135-2025

Levothyroxine Sodium Tablets, USP, 150 mcg (0.150 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 51079-445-20

Published December 18, 2024 · Recall initiated: November 19, 2024

Summary

FDA records drug Class II recall D-0135-2025, published December 18, 2024 and initiated November 19, 2024. Recalling firm: Mylan Institutional, Inc.; Status: Ongoing; Reported quantity: 690 cartons; Lot: Lot #: 3115924, Exp. Date 06/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent and Superpotent Drug

What to do

Voluntary: Firm initiated · Letter

Get an email if LEVOTHYROXINE SODIUM has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
LEVOTHYROXINE SODIUM
Manufacturer
Mylan Institutional, Inc.
Distributor
Nationwide in the USA.
Lot
Lot #: 3115924, Exp. Date 06/2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Levothyroxine Sodium Tablets, USP, 150 mcg (0.150 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 51079-445-20 recalled?

Yes. FDA published recall D-0135-2025 on December 18, 2024. Reported hazard: Subpotent and Superpotent Drug

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: LEVOTHYROXINE SODIUM.